Protect the Cow Herd and Get Calves Off to the Right Start
Flexibility in protocols gives producers best opportunity to protect the unborn calf
While spring calving season is just around the corner and fall calving herds are about to wean, it’s never too early to think about protecting the next calf crop by implementing a strong fetal protection vaccine program.
“It’s important to get that calf going good, and the right health all starts from the beginning,” said Cody Jorgensen, a partner in Jorgensen Land and Cattle near Ideal, South Dakota. “If you aren’t off to a good start, it’s a battle the rest of the way through that calf’s life.”
“What we’re doing by using fetal protection vaccines is that we are effectively protecting the calf prior to birth. If you couple that with a proper nutritional program, we’re setting that calf up for success in being able to reach its full genetic potential, from the time it’s conceived all the way through the production cycle,” says Mark Alley, DVM, Technical Services veterinarian with Zoetis.
While research has shown that a modified-live vaccination program can be highly effective in helping prevent abortions caused by infectious bovine rhinotracheitis (IBR) and persistent infection caused by bovine viral diarrhea (BVD) viruses Types 1 and 2, maintaining a strictly modified-live vaccination program that fits the cattle working schedule can be challenging for veterinarians and producers alike.
A nearly three-year study at Auburn University evaluated the efficacy of a vaccination program where heifers were all vaccinated with two doses of a modified-live reproductive vaccine (BOVI-SHIELD GOLD FP® 5) prior to breeding.1 At pregnancy check, the vaccinated heifers were split into two groups — one continued to get BOVI-SHIELD GOLD FP 5 and a second group was given CATTLEMASTER GOLD FP® 5. The study also maintained a control group, which received no vaccinations.
Study results in the control group revealed the severity of the challenge model with 14 of 15 cows either aborting BVD-positive calves or delivering a BVD persistently infected calf. Researchers observed significant (p < 0.0001) protection against both virulent BVD and IBR exposure in the vaccinated groups with both vaccine groups providing similarly high levels of protection.1
Dr. Alley says it is important for producers and veterinarians to look at the labels to make sure they are selecting vaccines that are effective in protecting against the reproductive forms of these important diseases. This means looking for the following information on the vaccine label:
- “FP” in the name of the product, which is a designation that the vaccine provides fetal protection
- Indication to prevent or control IBR-related abortions
- Indication to prevent or control BVD persistently infected calves
Producers are encouraged to visit with their veterinarian or local Zoetis representative about developing an effective fetal protection program or visit FetalCalfProtection.com for more information.
Do not use in pregnant cows (abortions can result) unless they were vaccinated, according to label directions, with any BOVI-SHIELD GOLD FP or PREGGUARD GOLD FP® vaccine prebreeding initially and within 12 months thereafter. Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above. To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any BOVI-SHIELD GOLD FP or PREGGUARD GOLD FP vaccine with the second dose administered approximately 30 days prebreeding.
Zoetis (NYSE: ZTS) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.